Giovanni Adami

Dr. Giovanni Adami

Medicine, University of Verona, Verona, Veneto, Italy
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
Verified
Journal Article
Closed access
PDF file
AFAngelo Fassio
Angelo Fassio
LILuca Idolazzi
Luca Idolazzi
MRMaurizio Rossini
Maurizio Rossini
DGDavide Gatti
Davide Gatti
GAGiovanni Adami
Giovanni Adami
OVOmbretta Viapiana
Ombretta Viapiana

25 February 2019 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
GAGiovanni Adami
Giovanni Adami
KSKenneth Saag
Kenneth Saag

Verified
Journal Article
Open access
PDF file
GAGiovanni Adami
Giovanni Adami
AFAngelo Fassio
Angelo Fassio
MRMaurizio Rossini
Maurizio Rossini
CCCristian Caimmi
Cristian Caimmi
AGAlessandro Giollo
Alessandro Giollo
DGDavide Gatti
Davide Gatti
Osteoporosis is a chronic disease characterized by an increased risk of fragility fracture. Patients affected by rheumatic diseases are at greater risk of developing osteoporosis. The purpose of the present review is to discuss the pathogenesis, epidemiology, and treatment of osteoporosis in patients affected by rheumatic diseases with special focus for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, vasculitides, Sjogren syndrome, and crystal-induced arthritis.

22 December 2021 in Frontiers in Public Health
Verified
Journal Article
Open access
Iacopo ChiodiniIacopo Chiodini
Iacopo Chiodini
DGDavide Gatti
Davide Gatti
DSDavide Soranna
Davide Soranna
DMDaniela Merlotti
Daniela Merlotti
CMChristian Mingiano
Christian Mingiano
LGLuigi Gennari
Luigi Gennari
Background: Several studies suggest an association between serum 25-hydroxyvitamin D (25OHD) and the outcomes of Severe Acute Respiratory Syndrome Corona-Virus-2 (SARS-CoV-2) infection, in particular Coronavirus Disease-2019 (COVID-19) related severity and mortality. The aim of the present meta-analysis was to investigate whether vitamin D status is associated with the COVID-19 severity, defined as ARDS requiring admission to intensive care unit (ICU) or mortality (primary endpoints) and with the susceptibility to SARS-CoV-2 and COVID-19-related hospitalization (secondary endpoints).Methods: A search in PubMed, ScienceDirect, Web of Science, Google Scholar, Scopus, and preprints repositories was performed until March 31th 2021 to identify all original observational studies reporting association measures, or enough data to calculate them, between Vitamin D status (insufficiency <75, deficiency <50, or severe deficiency <25 nmol/L) and risk of SARS-CoV-2 infection, COVID-19 hospitalization, ICU admission, or death during COVID-19 hospitalization.Findings: Fifty-four studies (49 as fully-printed and 5 as pre-print publications) were included for a total of 1,403,715 individuals. The association between vitamin D status and SARS-CoV2 infection, COVID-19 related hospitalization, COVID-19 related ICU admission, and COVID-19 related mortality was reported in 17, 9, 27, and 35 studies, respectively. Severe deficiency, deficiency and insufficiency of vitamin D were all associated with ICU admission (odds ratio [OR], 95% confidence intervals [95%CIs]: 2.63, 1.45–4.77; 2.16, 1.43–3.26; 2.83, 1.74–4.61, respectively), mortality (OR, 95%CIs: 2.60, 1.93–3.49; 1.84, 1.26–2.69; 4.15, 1.76–9.77, respectively), SARS-CoV-2 infection (OR, 95%CIs: 1.68, 1.32–2.13; 1.83, 1.43–2.33; 1.49, 1.16–1.91, respectively) and COVID-19 hospitalization (OR, 95%CIs 2.51, 1.63–3.85; 2.38, 1.56–3.63; 1.82, 1.43–2.33). Considering specific subgroups (i.e., Caucasian patients, high quality studies, and studies reporting adjusted association estimates) the results of primary endpoints did not change.Interpretations: Patients with low vitamin D levels present an increased risk of ARDS requiring admission to intensive care unit (ICU) or mortality due to SARS-CoV-2 infection and a higher susceptibility to SARS-CoV-2 infection and related hospitalization.

1 February 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
GAGiovanni Adami
Giovanni Adami
MPMarco Pontalti
Marco Pontalti
GCGiorgio Cattani
Giorgio Cattani
MRMaurizio Rossini
Maurizio Rossini
OVOmbretta Viapiana
Ombretta Viapiana
AFAngelo Fassio
Angelo Fassio
Objective: Environmental air pollution has been associated with disruption of the immune system at a molecular level. The primary aim of the present study was to describe the association between long-term exposure to air pollution and risk of developing immune-mediated conditions. Methods: We conducted a retrospective observational study on a nationwide dataset of women and men. Diagnoses of various immune-mediated diseases (IMIDs) were retrieved. Data on the monitoring of particulate matter (PM)10 and PM2.5 concentrations were retrieved from the Italian Institute of Environmental Protection and Research. Generalised linear models were employed to determine the relationship between autoimmune diseases prevalence and PM. Results: 81 363 subjects were included in the study. We found a positive association between PM10 and the risk of autoimmune diseases (ρ+0.007, p 0.014). Every 10 µg/m3 increase in PM10 concentration was associated with an incremental 7% risk of having autoimmune disease. Exposure to PM10 above 30 µg/m3 and PM2.5 above 20 µg/m3 was associated with a 12% and 13% higher risk of autoimmune disease, respectively (adjusted OR (aOR) 1.12, 95% CI 1.05 to 1.20, and aOR 1.13, 95% CI 1.06 to 1.20). Exposure to PM10 was associated with an increased risk of rheumatoid arthritis; exposure to PM2.5 was associated with an increased risk of rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD). Conclusion: Long-term exposure to air pollution was associated with higher risk of developing autoimmune diseases, in particular rheumatoid arthritis, CTDs and IBD. Chronic exposure to levels above the threshold for human protection was associated with a 10% higher risk of developing IMIDs.

23 May 2019 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
GAGiovanni Adami
Giovanni Adami
KSKenneth Saag
Kenneth Saag